PMID- 23583029
OWN - NLM
STAT- MEDLINE
DCOM- 20131209
LR  - 20130506
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Linking)
VI  - 47
IP  - 7
DP  - 2013 Jul
TI  - Additional ECT increases BDNF-levels in patients suffering from major depressive 
      disorders compared to patients treated with citalopram only.
PG  - 908-15
LID - S0022-3956(13)00089-7 [pii]
LID - 10.1016/j.jpsychires.2013.03.006 [doi]
AB  - BACKGROUND: In patients suffering from major depressive disorders (MDD), 
      improvements in MDD are related to increased activation of brain-derived 
      neurotrophic factor (BDNF), an endogenous protein that facilitates neural 
      functioning. To treat patients suffering from severe MDD, electroconvulsive 
      therapy (ECT) is considered an efficacious and safe intervention, though the 
      impact of ECT on plasma BDNF levels has thus far barely been investigated. The 
      aim of the present study was therefore to assess plasma BDNF levels and 
      depression of patients suffering from severe MDD treated with additional ECT 
      compared to patients treated with citalopram only. METHODS: A total of 40 
      patients (mean age: M = 31.45 years; females 30%) suffering from MDD and all 
      receiving 40 mg/d citalopram were assigned either to a control group (N = 20), or 
      to a target group (N = 20) undergoing additional 12 sessions of ECT. Plasma BDNF 
      and symptom severity were assessed at baseline and four weeks later. RESULTS: 
      Plasma BDNF increased in both groups over time, though the significant Time by 
      Group-interaction revealed an increase of 101% in the target group as compared to 
      the control group. Symptom severity significantly decreased in both groups over 
      time, though without being related to plasma BDNF levels. CONCLUSIONS: Data from 
      the present study suggest that, in patients suffering from severe MDD, treatment 
      with citalopram was associated both with an increase of plasma BDNF and 
      amelioration of depression, while additional ECT was associated with even higher 
      plasma BDNF levels. Further studies should focus on possible cognitive and 
      behavioral consequences.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Haghighi, Mohammad
AU  - Haghighi M
AD  - Research Center for Behavioral Disorders and Substances Abuse, Hamadan University 
      of Medical Sciences, Hamadan, Iran.
FAU - Salehi, Iraj
AU  - Salehi I
FAU - Erfani, Parichehr
AU  - Erfani P
FAU - Jahangard, Leila
AU  - Jahangard L
FAU - Bajoghli, Hafez
AU  - Bajoghli H
FAU - Holsboer-Trachsler, Edith
AU  - Holsboer-Trachsler E
FAU - Brand, Serge
AU  - Brand S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20130409
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents, Second-Generation/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Citalopram/*therapeutic use
MH  - Depressive Disorder, Major/*blood/*therapy
MH  - *Electroconvulsive Therapy
MH  - Female
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Male
MH  - Psychiatric Status Rating Scales
EDAT- 2013/04/16 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/01/18 00:00 [received]
PHST- 2013/03/06 00:00 [revised]
PHST- 2013/03/06 00:00 [accepted]
PHST- 2013/04/16 06:00 [entrez]
PHST- 2013/04/16 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S0022-3956(13)00089-7 [pii]
AID - 10.1016/j.jpsychires.2013.03.006 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2013 Jul;47(7):908-15. doi: 10.1016/j.jpsychires.2013.03.006. 
      Epub 2013 Apr 9.